Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-016257
Filing Date
2022-08-10
Accepted
2022-08-10 07:16:21
Documents
63
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tngx-20220630.htm   iXBRL 10-Q 3175480
2 EX-31.1 tngx-ex31_1.htm EX-31.1 19564
3 EX-31.2 tngx-ex31_2.htm EX-31.2 19435
4 EX-32.1 tngx-ex32_1.htm EX-32.1 9477
5 EX-32.2 tngx-ex32_2.htm EX-32.2 9473
  Complete submission text file 0000950170-22-016257.txt   8874054

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tngx-20220630_def.xml EX-101.DEF 200783
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tngx-20220630_lab.xml EX-101.LAB 381869
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tngx-20220630.xsd EX-101.SCH 45974
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tngx-20220630_pre.xml EX-101.PRE 286144
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tngx-20220630_cal.xml EX-101.CAL 39528
57 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20220630_htm.xml XML 1490138
Mailing Address 100 BINNEY ST SUITE 700 CAMBRIDGE MA 02142
Business Address 100 BINNEY ST SUITE 700 CAMBRIDGE MA 02142 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 221150394
SIC: 2834 Pharmaceutical Preparations